What can ACQUITY PREMIER do for your oligonucleotide analysis?

Význam tématu

Accurate and reproducible analysis of synthetic oligonucleotides is critical for quality control in therapeutics, diagnostics, and research. Surface adsorption and sample loss during liquid chromatography can compromise sensitivity and data reliability. The ACQUITY PREMIER system addresses these challenges by integrating advanced surface passivation and optimized stationary phases to minimize analyte‐surface interactions.

Cíle a přehled studie / článku

This study evaluates the performance of the Waters ACQUITY PREMIER UPLC platform equipped with Oligonucleotide C18 columns (130 Å, 1.7 µm) and optional BEH C18 300 Å hardware for oligonucleotide analysis. Key objectives include assessing recovery, repeatability, and peak shape across a range of oligo chain lengths (15–35 mers) without extensive column conditioning.

Použitá metodika a instrumentace

Samples comprised 10 pmol injections of standards diluted in water. Reversed‐phase separations were performed using mobile phases compatible with HFIP, HAA (hexafluoro-isopropanol/alkylamine), and TEA (triethylamine) chemistries. Passivation steps involved an initial 500 pmol injection of a 35 mer followed by a 10 pmol standard to stabilize surface interactions.

Použitá instrumentace

• Waters ACQUITY PREMIER UPLC system
• Oligonucleotide BEH C18, 130 Å, 1.7 µm (dimensions: 2.1 × 50, 100, 150 mm)
• Peptide BEH C18, 300 Å, 1.7 µm (dimensions: 2.1 × 50, 100, 150 mm)*
• MaxPeak High Performance Surfaces for reduced adsorption

Hlavní výsledky a diskuse

ACQUITY PREMIER delivered full analyte recovery from the first injection, contrasting with conventional columns that required multiple pre‐runs. Recoveries for 15–35 mers consistently exceeded 98% with relative standard deviations below 3%. Peak capacity and shape improved markedly under HFIP, HAA, and TEA conditions. The MaxPeak passivation strategy yielded stable performance across sequential injections, reducing reconditioning time and solvent consumption.

Přínosy a praktické využití metody

• High sensitivity and reproducibility for oligonucleotide QC and method validation
• Elimination of lengthy column equilibration and sample carryover
• Compatibility with MS detection through reduced metal leachates and fouling
• Scalable workflows for therapeutic development, genomic assays, and impurity profiling

Budoucí trendy a možnosti využití

Ongoing advances may integrate PREMIER surfaces with automated sample preparation and high-resolution mass spectrometry for deeper oligo characterization. Novel surface chemistries and alternative stationary phases could further minimize nonspecific binding. Applications will expand into longer synthetic RNAs, mRNA vaccines, and multiplexed biomarker panels.

Závěr

The ACQUITY PREMIER UPLC system, combined with MaxPeak High Performance Surfaces and dedicated C18 phases, provides out-of-the-box robustness for oligonucleotide separations. It ensures rapid method deployment, high recovery, and exceptional repeatability, making it a valuable tool for analytical laboratories in biotechnology and pharmaceutical development.

Reference

No external literature references were provided in the source document.